We developed in-house an experimental glucocorticoid-based molecule. The small molecule we designed exhibits a unique mode of action consisting of validated anti-inflammatory effects combined with a much safer side effect profile in vivo, as established using rodent models. The aim of our proposal is to translate these well-defined pre-track findings to the relevant end-users in practice. For this we will study early ADMET results in dog cells and undertake a safety study in dogs. The results of our study will allow us to 1) generate IP 2) to set up a follow-up efficacy study in chronic inflammatory disease models in dogs as relevant end users 3) continue negotiations with the veterinary market, and 4) proceed with a tool to lead compound study. As the physiological response to steroids is more similar in man and dog, the results of the proposed research will reinforce the safety dataset for humans.